Human CXCL10 ELISA kit
- Known as:
- Human CXCL10 Enzyme-linked immunosorbent assay test reagent
- Catalog number:
- LF-EK50717
- Product Quantity:
- 1
- Category:
- Elisa Kits
- Supplier:
- Abfron
- Gene target:
- Human CXCL10 ELISA kit
Related genes to: Human CXCL10 ELISA kit
- Gene:
- CXCL10 NIH gene
- Name:
- C-X-C motif chemokine ligand 10
- Previous symbol:
- INP10, SCYB10
- Synonyms:
- IFI10, IP-10, crg-2, mob-1, C7, gIP-10
- Chromosome:
- 4q21.1
- Locus Type:
- gene with protein product
- Date approved:
- 1999-12-09
- Date modifiied:
- 2016-10-05
Related products to: Human CXCL10 ELISA kit
Related articles to: Human CXCL10 ELISA kit
- This study aimed to investigate whether propofol-remifentanil anesthesia offers superior perioperative outcomes compared to propofol-fentanyl in pancreatic cancer surgery patients, with a focus on its effects on apoptotic molecules, plasma CXCL10/CXCL13 levels, and postoperative recovery. A total of 150 pancreatic cancer patients were divided into 2 cohorts receiving either propofol-fentanyl (control group, n=75) or propofol-remifentanil (study group, n=75) anesthesia. We measured perioperative hemodynamics (cardiac index [CI], mean arterial pressure [MAP], heart rate [HR]), T-cell subsets, postoperative recovery indices (eye-opening time, extubation time, spontaneous respiration recovery time), sedation and analgesia levels (via Ramsay sedation score [RSS] and visual analog scale [VAS]), plasma CXCL10/CXCL13 levels, and apoptosis-related proteins (Survivin, Bax, Caspase-4, Bcl-2) using enzyme-linked immunosorbent assays (ELISAs). Adverse reactions were also recorded. The study group exhibited significant advantages in hemodynamic stability and immune preservation. Despite similar baseline cardiovascular parameters, the remifentanil group maintained better CI, MAP, and HR stability during and after surgery. Flow cytometry analysis revealed better preservation of T-cell immunity (CD4+, CD3+, CD4+/CD8+ T cells) at 24 hours post-surgery. The intervention group also demonstrated accelerated postoperative recovery with significantly reduced emergence times (eye-opening, extubation, spontaneous respiration). Notably, the study group had more favorable inflammatory profiles (lower CXCL10/CXCL13 levels) and enhanced apoptotic responses (modulated Bax, Caspase-4, Survivin, and Bcl-2 expression). Clinical outcomes were superior in the study group, with significantly fewer adverse events (2 vs. 9 patients). Propofol-remifentanil anesthesia provides effective sedation and analgesia in pancreatic cancer surgery, modulates key biological pathways related to apoptosis and inflammation, and improves postoperative recovery. These findings suggest that the choice of anesthesia regimen may have significant implications for perioperative outcomes and potentially long-term prognosis in pancreatic cancer patients. Future research should further explore the underlying mechanisms and long-term clinical benefits of this anesthesia strategy. - Source: PubMed
Publication date: 2026/08/10
Li YingTian YanchunGao JingDong ChuanyingChu Xiaonan - Interferon-responsive tumor-cell states can simultaneously increase immune visibility and induce immune-regulatory programs, yet their epithelial-cell distribution and treatment responsiveness in bladder cancer remain incompletely defined. We sought to resolve a reproducible epithelial interferon-response state across patients, characterize its immune context, and determine whether its transcriptional components respond to ionizing radiation . - Source: PubMed
Publication date: 2026/09/11
Ji YangZhang YangyangLiu XiaodongLv ZhuoyuanWang YakaiWu ShixuanWang Lei - Systemic administration of recombinant cytokines for immunomodulation in cancer and chronic infection is limited by toxicity and poor spatial control. Messenger RNA (mRNA)-encoded cytokines offer a programmable alternative, but the immunological consequences of interferon-β (IFN-β) mRNA delivery in primary human immune cells, and its compatibility with co-delivered antigen-encoding mRNA, remain incompletely defined. This study evaluated whether nucleoside-modified, mRNA-encoded human IFN-β can function as a multifunctional immunomodulator with pro-apoptotic activity and timing-dependent immunostimulatory properties. N1-methylpseudouridine-modified IFN-β mRNA was transfected into HEK293T and HepG2 cell lines and into primary human monocyte-derived dendritic cells (MDDCs) and M2-polarized macrophages (MDMs) using Lipofectamine MessengerMAX, with OVA mRNA as a non-adjuvant control. Apoptosis, interferon-stimulated CXCL10 secretion, activation marker expression, and cytokine profiles were assessed by flow cytometry, ELISA, Western blot, and cytometric bead array. Adjuvant activity was evaluated in MDDCs co-transfected with IFN-β and antigen (EGFP or OVA) mRNA under four temporal delivery regimens. IFN-β mRNA induced time-dependent apoptosis, most pronounced in HepG2 cells, and CXCL10 secretion in both cell lines. In primary immune cells, IFN-β mRNA activated MDDCs, increased pro-inflammatory cytokine secretion, and repolarized M2-like macrophages toward a pro-inflammatory phenotype. In co-transfection experiments, IFN-β mRNA enhanced MDDC activation across regimens, but antigen expression was preserved only when antigen mRNA was delivered before IFN-β mRNA. mRNA-encoded IFN-β combines direct pro-apoptotic activity with programmable, timing-dependent immunostimulatory effects, supporting its development as a component of next-generation mRNA-based immunotherapies and vaccines. - Source: PubMed
Publication date: 2026/09/20
Fraude-El Ghazi SilviaLimeres Maria JoséGambaro RocioPena Vaquero AnaPrawitt DirkIslan GermanGehring StephanCacicedo Maximiliano L - is a keystone periodontal pathogen strongly associated with periodontitis progression. Although testosterone levels have been associated with periodontal health, its direct effects on virulence remain poorly understood. The aim of this study was to investigate the impact of testosterone exposure on the key virulence characteristics of strain W50. We found that testosterone significantly increased the growth and biofilm biomass of W50 after 48 h. Furthermore, testosterone enhanced the extracellular gingipain activity of both lysine and arginine gingipains from . We also found that IL-1β release from gingival epithelial cells was significantly lowered following infection with testosterone-primed compared with unprimed W50. At the mRNA level, no differences in pro-IL-1β, IL-8, or CXCL10 gene expression were detected in gingival epithelial cells infected with testosterone-primed compared with unprimed W50. Finally, testosterone priming significantly enhanced the ability of to colonize and invade gingival epithelial cells. Overall, these findings indicate that testosterone exposure modulates several virulence-associated phenotypes of W50 in vitro. The mechanisms underlying these effects and their relevance to periodontal disease in vivo remain to be determined. - Source: PubMed
Publication date: 2026/09/07
Amba Kindlund YvetteWu RongrongJayaprakash Demirel KartheyaeneNeves Guimaraes AlessandraDemirel Isak - The classification of metabolic risk solely based on body mass index (BMI) fails to acknowledge the heterogeneity inherent in obesity. Soluble urokinase plasminogen activator receptor (suPAR) has been proposed as a stable biomarker of chronic inflammation; however, its behaviour across metabolic obesity phenotypes defined jointly by adiposity and insulin resistance remains uncertain. In this cross-sectional study, 190 adults aged 18 to 60 years attending internal medicine outpatient clinics were stratified by BMI (≥30 kg/m) and homeostasis model assessment of insulin resistance (HOMA-IR ≥ 2.5) into four phenotypes: non-obese insulin-sensitive (NOIS, = 64), non-obese insulin-resistant (NOIR, = 50), obese insulin-sensitive (OIS, = 33), and obese insulin-resistant (OIR, = 43). Serum suPAR, interleukin-6 (IL-6), and C-X-C motif chemokine ligand 10 (CXCL10) were measured using enzyme-linked immunosorbent assays. Group comparisons, rank-based two-factor analyses, correlation analyses, logistic regression, and receiver operating characteristic (ROC) analyses were performed. Serum suPAR did not differ across the four phenotypes ( = 0.19) and was not correlated with HOMA-IR (ρ = -0.09, = 0.24). IL-6 was lower in the OIR group than in the NOIS group ( = 0.012). CXCL10 was higher in both obese phenotypes than in both non-obese phenotypes ( < 0.001), and rank-based two-factor analysis attributed this difference to obesity ( < 0.001) rather than insulin resistance ( = 0.71). CXCL10 correlated with BMI (ρ = 0.29, < 0.001) and remained associated with obesity after adjustment for age, sex, and C-reactive protein (odds ratio per 10 ng/L, 1.12; 95% confidence interval, 1.06 to 1.18). CXCL10 discriminated obesity with an area under the ROC curve of 0.74 (95% CI, 0.66 to 0.81). None of the three biomarkers discriminated insulin resistance (areas under the curve, 0.43 to 0.50). The association between CXCL10 and obesity was consistent in both sexes and unchanged with alternative HOMA-IR cutoffs of 2.0 and 3.0. In this cohort, circulating CXCL10 tracked adiposity rather than insulin resistance, whereas suPAR and IL-6 did not separate metabolic obesity phenotypes. These findings do not support suPAR as a marker of insulin resistance independently of body fat. - Source: PubMed
Publication date: 2026/09/09
Acet AycanOzdemir CaglaSolak Hatice